東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Metabolite safety in drug development

Iverson, Suzanne L., (1971-)

FindBook

Google Book

Amazon

博客來

Metabolite safety in drug development

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Metabolite safety in drug development/ Suzanne L. Iverson, Dennis A. Smith.
作者:	Iverson, Suzanne L.,
其他作者:	Smith, Dennis A.,
出版者:	Hoboken, NJ :John Wiley & Sons Inc., : [2016],
面頁冊數:	xv, 331 pages ;25 cm
內容註:	Machine generated contents note: PREFACE LIST OF CONTRIBUTORS 1. Introduction: History of Metabolite Safety in Drug Development Dennis A. Smith and Suzanne L. Iverson 1.1. People, events and reaction 1.2. The rise of industrial drug metabolism 1.3. The appearance of MIST 1.4. The journey triggered by thalidomide- would present science have made a difference? 1.5. Key events from thalidomide to MIST 1.6. The purpose of this book 1.7. References 2. "MIST" and other metabolite guidelines in the context of industrial drug metabolism Gordon J. Dear and Angus N. R. Nedderman 2.1. A historical perspective 2.2. The emergence of the regulatory guidance documents 2.3. Impact of the guidelines 2.4. Future directions? 2.5. References 3. Metabolite technology - qualitative and quantitative Gordon J. Dear and Andrew McEwen 3.1. Introduction 3.2. Clinical Samples 3.3. Pre-Clinical Samples 3.4. Radiolabelled test compounds 3.5. Mass Spectrometry 3.6. Nuclear magnetic resonance Spectroscopy 3.7. Accelerator mass spectrometry (AMS) 3.8. Further Reading 3.9. References 4. In Vitro methods for evaluation of drug metabolism: Identification of active and inactive metabolites and the enzymes that generate them R. Scott Obach, Amit S. Kalgutkar, and Deepak K. Dalvie 4.1. Introduction 4.2. The in vitro methods for metabolite profiling and identification 4.3. Application of in vitro methods for metabolite profiling in drug discovery and development 4.4. How well do in vitro metabolite profiles present in vivo metabolite profiles? 4.5 Pharmacologically active metabolites and their identification 4.6 Conclusion 5. Integrated reactive metabolite strategies J. Gerry Kenna and Richard A. Thompson 5.1 Introduction 5.2 Role of RMs in toxicity 5.3. Strategies for predicting, assessing and de-risking RM mediated toxicity 5.4. References 6. Understanding drug metabolism in humans - in vivo Lars Weidolf and Ian D. Wilson 6.1. Abstract 6.2. Introduction 6.3. Preclinical Animal Studies 6.4. Early human in vivo metabolism studies 6.5. Sources of Variability in in vivo Biotransformation Studies: Species, Strain, Age and Sex differences 6.6. Extra-hepatic drug metabolism (animals and man) 6.7. Non-human metabolism in humans 6.8. Non-human models of human in vivo metabolism 6.9. Alternatives to Radiolabels 6.10. Conclusions 6.11. References 7. Topical administration and safety testing of metabolites Vibeke Hougaard Sunesen 7.1. Introduction 7.2. Skin structure and function of the epidermal layer 7.3. Skin models 7.4. Metabolic capacity of human skin 7.5. Species differences in metabolic capacity of the skin 7.6. Metabolic capacity of diseased skin 7.7. Soft drug approach 7.8. Exposure to metabolites and risk of adverse events 7.9. References 8. In Silico Modelling of Metabolite Kinetics Lu Gaohua, Howard Burt, Helen Humphries, Amin Rostami-Hodjegan, Masoud Jamei 8.1. In Silico Modelling of Metabolite Kinetics 8.2. Simcyp approach to modelling metabolite PBPK 8.3. Model verifications 8.4. Discussion 8.5. Concluding Remarks 8.6. Glossary 8.7. References 9. Introduction to Case Studies Suzanne L. Iverson References 10. A mass balance and metabolite profiling study of sonidegib in healthy male subjects using microtrace approach Piet Swart, Frederic Lozac'h, and Markus Zollinger 10.1. Introduction to the study 10.2. Radioactive dose limitations 10.3. Results 10.4. Metabolite profiling and identification 10.5. References 11. Dealing With Reality - When is it necessary to qualify and quantify metabolites? Some Case Studies Deepak K. Dalvie, R. Scott Obach and Amit S. Kalgutkar 11.1. Introduction 11.2. Case study 1 11.3. Case study 2 11.4. Case study 3 11.5. References 12. CASE STUDIES GlaxoSmithKline Jackie Bloomer, Claire Beaumont, Gordon Dear, Stephanie North and Graeme Young 12.1. GW644784: Species Specific Metabolites 12.2. Danirixin: Assessment of Victim Drug Interaction Risk Using Bile Sampling 12.3. Sitamaquine: Unique, Active and Possible Genotoxic Metabolites and Human Radiolabel Study Not Feasible 12.4. SB-773812: Concerns Over Long Half-life Metabolite and Early Employment of Accelerator Mass Spectrometry 12.5. GW766994: Consideration of Steady State Kinetics and Multiple Analytical Methodologies for an Accurate Assessment of Human Metabolism 12.6. References 13. The importance of dose- and time- dependent pharmacokinetics during early metabolite safety assessment in humans Laurent Leclercq, Marc Bockx, Hilde Bohets, Hans Stieltjes, Vikash Sinah and Ellen Scheers 13.1. References 14. MIST and the future B. Kevin Park and Dennis A. Smith 14.1. Introduction 14.2. MIST and Pharmacology 14.3. Reactive metabolites, pharmacology and MIST 14.4. Implications of drug bioactivation and covalent binding for MIST 14.5. Implications of drug bioactivation and covalent binding for MIST 14.6. Drug-conjugate formation and Drug Hypersensitivity 14.7. Drug bioactivation, conjugate formation and drug hypersensitivity 14.8. Towards a MIST strategy for reactive metabolites 14.9. References.
標題:	Drugs - Metabolism. -
電子資源:	http://onlinelibrary.wiley.com/book/10.1002/9781118949689
ISBN:	9781118949689 (ebk.)

Metabolite safety in drug development
Iverson, Suzanne L.,1971-

Metabolite safety in drug development[electronic resource] /Suzanne L. Iverson, Dennis A. Smith. - Hoboken, NJ :John Wiley & Sons Inc.,[2016] - xv, 331 pages ;25 cm

Includes bibliographical references and index.

Machine generated contents note: PREFACE LIST OF CONTRIBUTORS 1. Introduction: History of Metabolite Safety in Drug Development Dennis A. Smith and Suzanne L. Iverson 1.1. People, events and reaction 1.2. The rise of industrial drug metabolism 1.3. The appearance of MIST 1.4. The journey triggered by thalidomide- would present science have made a difference? 1.5. Key events from thalidomide to MIST 1.6. The purpose of this book 1.7. References 2. "MIST" and other metabolite guidelines in the context of industrial drug metabolism Gordon J. Dear and Angus N. R. Nedderman 2.1. A historical perspective 2.2. The emergence of the regulatory guidance documents 2.3. Impact of the guidelines 2.4. Future directions? 2.5. References 3. Metabolite technology - qualitative and quantitative Gordon J. Dear and Andrew McEwen 3.1. Introduction 3.2. Clinical Samples 3.3. Pre-Clinical Samples 3.4. Radiolabelled test compounds 3.5. Mass Spectrometry 3.6. Nuclear magnetic resonance Spectroscopy 3.7. Accelerator mass spectrometry (AMS) 3.8. Further Reading 3.9. References 4. In Vitro methods for evaluation of drug metabolism: Identification of active and inactive metabolites and the enzymes that generate them R. Scott Obach, Amit S. Kalgutkar, and Deepak K. Dalvie 4.1. Introduction 4.2. The in vitro methods for metabolite profiling and identification 4.3. Application of in vitro methods for metabolite profiling in drug discovery and development 4.4. How well do in vitro metabolite profiles present in vivo metabolite profiles? 4.5 Pharmacologically active metabolites and their identification 4.6 Conclusion 5. Integrated reactive metabolite strategies J. Gerry Kenna and Richard A. Thompson 5.1 Introduction 5.2 Role of RMs in toxicity 5.3. Strategies for predicting, assessing and de-risking RM mediated toxicity 5.4. References 6. Understanding drug metabolism in humans - in vivo Lars Weidolf and Ian D. Wilson 6.1. Abstract 6.2. Introduction 6.3. Preclinical Animal Studies 6.4. Early human in vivo metabolism studies 6.5. Sources of Variability in in vivo Biotransformation Studies: Species, Strain, Age and Sex differences 6.6. Extra-hepatic drug metabolism (animals and man) 6.7. Non-human metabolism in humans 6.8. Non-human models of human in vivo metabolism 6.9. Alternatives to Radiolabels 6.10. Conclusions 6.11. References 7. Topical administration and safety testing of metabolites Vibeke Hougaard Sunesen 7.1. Introduction 7.2. Skin structure and function of the epidermal layer 7.3. Skin models 7.4. Metabolic capacity of human skin 7.5. Species differences in metabolic capacity of the skin 7.6. Metabolic capacity of diseased skin 7.7. Soft drug approach 7.8. Exposure to metabolites and risk of adverse events 7.9. References 8. In Silico Modelling of Metabolite Kinetics Lu Gaohua, Howard Burt, Helen Humphries, Amin Rostami-Hodjegan, Masoud Jamei 8.1. In Silico Modelling of Metabolite Kinetics 8.2. Simcyp approach to modelling metabolite PBPK 8.3. Model verifications 8.4. Discussion 8.5. Concluding Remarks 8.6. Glossary 8.7. References 9. Introduction to Case Studies Suzanne L. Iverson References 10. A mass balance and metabolite profiling study of sonidegib in healthy male subjects using microtrace approach Piet Swart, Frederic Lozac'h, and Markus Zollinger 10.1. Introduction to the study 10.2. Radioactive dose limitations 10.3. Results 10.4. Metabolite profiling and identification 10.5. References 11. Dealing With Reality - When is it necessary to qualify and quantify metabolites? Some Case Studies Deepak K. Dalvie, R. Scott Obach and Amit S. Kalgutkar 11.1. Introduction 11.2. Case study 1 11.3. Case study 2 11.4. Case study 3 11.5. References 12. CASE STUDIES GlaxoSmithKline Jackie Bloomer, Claire Beaumont, Gordon Dear, Stephanie North and Graeme Young 12.1. GW644784: Species Specific Metabolites 12.2. Danirixin: Assessment of Victim Drug Interaction Risk Using Bile Sampling 12.3. Sitamaquine: Unique, Active and Possible Genotoxic Metabolites and Human Radiolabel Study Not Feasible 12.4. SB-773812: Concerns Over Long Half-life Metabolite and Early Employment of Accelerator Mass Spectrometry 12.5. GW766994: Consideration of Steady State Kinetics and Multiple Analytical Methodologies for an Accurate Assessment of Human Metabolism 12.6. References 13. The importance of dose- and time- dependent pharmacokinetics during early metabolite safety assessment in humans Laurent Leclercq, Marc Bockx, Hilde Bohets, Hans Stieltjes, Vikash Sinah and Ellen Scheers 13.1. References 14. MIST and the future B. Kevin Park and Dennis A. Smith 14.1. Introduction 14.2. MIST and Pharmacology 14.3. Reactive metabolites, pharmacology and MIST 14.4. Implications of drug bioactivation and covalent binding for MIST 14.5. Implications of drug bioactivation and covalent binding for MIST 14.6. Drug-conjugate formation and Drug Hypersensitivity 14.7. Drug bioactivation, conjugate formation and drug hypersensitivity 14.8. Towards a MIST strategy for reactive metabolites 14.9. References.

"A reference on drug metabolism and metabolite safety in the development phase, this book reviews the analytical techniques and experimental designs critical for metabolite studies. It features case studies of lessons learned and real world examples, along with regulatory perspectives from the US FDA and EMA. •    Reviews the analytical techniques and experimental designs critical for metabolite studies •    Covers methods including chirality, species differences, mass spectrometry, radiolabels, and in vitro / in vivo correlation •    Discusses target pharmacology, in vitro systems aligned to toxicity tests, and drug-drug interactions •    Includes perspectives from authors with firsthand involvement in industry and the study of drug metabolites, including viewpoints that have influenced regulatory guidelines"--

ISBN: 9781118949689 (ebk.)

LCCN: 2016009167Subjects--Topical Terms:

683549
Drugs
--Metabolism.

LC Class. No.: RM301.55 / .I94 2016

Dewey Class. No.: 615.1

Metabolite safety in drug development
LDR:06950cmm 22002538i 4500 001 2036975
005 19991122085710.0
008 161123s2016 nju b 001 0 eng
010 $a 2016009167
020 $a 9781118949689 (ebk.)
020 $a 9781118949658 (hbk.)
035 $a 9781118949689
040 $a DLC $b eng $e rda $c DLC
042 $a pcc
050 0 0 $a RM301.55 $b .I94 2016
082 0 0 $a 615.1 $2 23
084 $a SCI013010 $a MED071000 $2 bisacsh
100 1 $a Iverson, Suzanne L., $d 1971- $e author. $3 2193353
245 1 0 $a Metabolite safety in drug development $h [electronic resource] / $c Suzanne L. Iverson, Dennis A. Smith.
260 # $a Hoboken, NJ : $b John Wiley & Sons Inc., $c [2016]
300 $a xv, 331 pages ; $c 25 cm
504 $a Includes bibliographical references and index.
505 8 # $a Machine generated contents note: PREFACE LIST OF CONTRIBUTORS 1. Introduction: History of Metabolite Safety in Drug Development Dennis A. Smith and Suzanne L. Iverson 1.1. People, events and reaction 1.2. The rise of industrial drug metabolism 1.3. The appearance of MIST 1.4. The journey triggered by thalidomide- would present science have made a difference? 1.5. Key events from thalidomide to MIST 1.6. The purpose of this book 1.7. References 2. "MIST" and other metabolite guidelines in the context of industrial drug metabolism Gordon J. Dear and Angus N. R. Nedderman 2.1. A historical perspective 2.2. The emergence of the regulatory guidance documents 2.3. Impact of the guidelines 2.4. Future directions? 2.5. References 3. Metabolite technology - qualitative and quantitative Gordon J. Dear and Andrew McEwen 3.1. Introduction 3.2. Clinical Samples 3.3. Pre-Clinical Samples 3.4. Radiolabelled test compounds 3.5. Mass Spectrometry 3.6. Nuclear magnetic resonance Spectroscopy 3.7. Accelerator mass spectrometry (AMS) 3.8. Further Reading 3.9. References 4. In Vitro methods for evaluation of drug metabolism: Identification of active and inactive metabolites and the enzymes that generate them R. Scott Obach, Amit S. Kalgutkar, and Deepak K. Dalvie 4.1. Introduction 4.2. The in vitro methods for metabolite profiling and identification 4.3. Application of in vitro methods for metabolite profiling in drug discovery and development 4.4. How well do in vitro metabolite profiles present in vivo metabolite profiles? 4.5 Pharmacologically active metabolites and their identification 4.6 Conclusion 5. Integrated reactive metabolite strategies J. Gerry Kenna and Richard A. Thompson 5.1 Introduction 5.2 Role of RMs in toxicity 5.3. Strategies for predicting, assessing and de-risking RM mediated toxicity 5.4. References 6. Understanding drug metabolism in humans - in vivo Lars Weidolf and Ian D. Wilson 6.1. Abstract 6.2. Introduction 6.3. Preclinical Animal Studies 6.4. Early human in vivo metabolism studies 6.5. Sources of Variability in in vivo Biotransformation Studies: Species, Strain, Age and Sex differences 6.6. Extra-hepatic drug metabolism (animals and man) 6.7. Non-human metabolism in humans 6.8. Non-human models of human in vivo metabolism 6.9. Alternatives to Radiolabels 6.10. Conclusions 6.11. References 7. Topical administration and safety testing of metabolites Vibeke Hougaard Sunesen 7.1. Introduction 7.2. Skin structure and function of the epidermal layer 7.3. Skin models 7.4. Metabolic capacity of human skin 7.5. Species differences in metabolic capacity of the skin 7.6. Metabolic capacity of diseased skin 7.7. Soft drug approach 7.8. Exposure to metabolites and risk of adverse events 7.9. References 8. In Silico Modelling of Metabolite Kinetics Lu Gaohua, Howard Burt, Helen Humphries, Amin Rostami-Hodjegan, Masoud Jamei 8.1. In Silico Modelling of Metabolite Kinetics 8.2. Simcyp approach to modelling metabolite PBPK 8.3. Model verifications 8.4. Discussion 8.5. Concluding Remarks 8.6. Glossary 8.7. References 9. Introduction to Case Studies Suzanne L. Iverson References 10. A mass balance and metabolite profiling study of sonidegib in healthy male subjects using microtrace approach Piet Swart, Frederic Lozac'h, and Markus Zollinger 10.1. Introduction to the study 10.2. Radioactive dose limitations 10.3. Results 10.4. Metabolite profiling and identification 10.5. References 11. Dealing With Reality - When is it necessary to qualify and quantify metabolites? Some Case Studies Deepak K. Dalvie, R. Scott Obach and Amit S. Kalgutkar 11.1. Introduction 11.2. Case study 1 11.3. Case study 2 11.4. Case study 3 11.5. References 12. CASE STUDIES GlaxoSmithKline Jackie Bloomer, Claire Beaumont, Gordon Dear, Stephanie North and Graeme Young 12.1. GW644784: Species Specific Metabolites 12.2. Danirixin: Assessment of Victim Drug Interaction Risk Using Bile Sampling 12.3. Sitamaquine: Unique, Active and Possible Genotoxic Metabolites and Human Radiolabel Study Not Feasible 12.4. SB-773812: Concerns Over Long Half-life Metabolite and Early Employment of Accelerator Mass Spectrometry 12.5. GW766994: Consideration of Steady State Kinetics and Multiple Analytical Methodologies for an Accurate Assessment of Human Metabolism 12.6. References 13. The importance of dose- and time- dependent pharmacokinetics during early metabolite safety assessment in humans Laurent Leclercq, Marc Bockx, Hilde Bohets, Hans Stieltjes, Vikash Sinah and Ellen Scheers 13.1. References 14. MIST and the future B. Kevin Park and Dennis A. Smith 14.1. Introduction 14.2. MIST and Pharmacology 14.3. Reactive metabolites, pharmacology and MIST 14.4. Implications of drug bioactivation and covalent binding for MIST 14.5. Implications of drug bioactivation and covalent binding for MIST 14.6. Drug-conjugate formation and Drug Hypersensitivity 14.7. Drug bioactivation, conjugate formation and drug hypersensitivity 14.8. Towards a MIST strategy for reactive metabolites 14.9. References.
520 # $a "A reference on drug metabolism and metabolite safety in the development phase, this book reviews the analytical techniques and experimental designs critical for metabolite studies. It features case studies of lessons learned and real world examples, along with regulatory perspectives from the US FDA and EMA. •    Reviews the analytical techniques and experimental designs critical for metabolite studies •    Covers methods including chirality, species differences, mass spectrometry, radiolabels, and in vitro / in vivo correlation •    Discusses target pharmacology, in vitro systems aligned to toxicity tests, and drug-drug interactions •    Includes perspectives from authors with firsthand involvement in industry and the study of drug metabolites, including viewpoints that have influenced regulatory guidelines"-- $c Provided by publisher.
520 # $a "This book focuses on the characterization of metabolites once a drug candidate is selected, featuring case studies to illustrate lessons learned and a perspective on future directions"-- $c Provided by publisher.
650 # 0 $a Drugs $x Metabolism. $3 683549
650 # 0 $a Drugs $x Safety measures. $3 916099
650 # 0 $a Pharmacology. $3 634543
650 # 7 $a SCIENCE / Chemistry / Analytic. $2 bisacsh $3 2193355
650 # 7 $a MEDICAL / Pharmacology. $2 bisacsh $3 2193356
700 1 # $a Smith, Dennis A., $e author. $3 2193354
856 4 0 $u http://onlinelibrary.wiley.com/book/10.1002/9781118949689